IS'ECHO : Impact of Bursitis on the Efficacy of Subacromial Steroid Injection in Rotator Cuff Tendinopathy

Rotator Cuff Tendinopathy Clinical Trial

— IS'ECHO  

Official title:

Is the Presence of Subacromial Bursitis Associated With a Good Response to Ultrasound-guided Steroid Injection in Rotator Cuff Tendinopathy?

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03454321
• Other study ID #: RC17_0496
• Status: Completed
• Start date: March 15, 2018
• Est. completion date: September 1, 2021

Study information

• Verified date: September 2021
• Source: Nantes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Shoulder pain is a common reason for medical consultation affecting 6.7 % of the adults from 50 to 70 years old and until 21 % of the adults over 70. Among these painful shoulders, rotator cuff tendinopathy represents 44 to 65% of these consultations. To treat this condition, patients usually receive analgesics and physical therapy. When these treatments are not effective, a corticosteroid sub-acromial injection is proposed. However, according to the literature, there is only about 50% of good response to this subacromial injection in rotator cuff tendinopathy. It has been suggested that the injection could be more effective in the presence of an inflammation over the tendons called bursitis. However, no studies have clearly established this. The objective of the study is to determine if the presence of a bursitis could be a factor of good response to corticosteroid injection. The results could allow us to determine which patients have the best profile to respond to subacromial injection. The investigators hope that these data would improve the treatment of this frequent disease.

Description:

Patients referred to receive a subacromial ultrasound-guided injection for shoulder pain related to a rotator cuff tendinopathy will be enrolled in the study. After validation of the inclusion criteria, the participants will receive oral information about the protocol. Then, they will be examined and will undergo X-rays and an ultrasound of their shoulder. Pain shoulder and shoulder disability will be assessed before the injection with a visual analogic pain scale and the Oxford Shoulder Score questionnaire, respectively. The subacromial injection will be performed under ultrasound guidance to accurately inject the subacromial bursae. After skin disinfection with povidone, the injection will be performed with a 21G needle. The bursae will be injected with 2 ml of lidocaine 2% and 1 ml of betamethasone. After the procedure, the participants will all receive a standardized physiotherapy. For primary outcome, the therapeutic response will be assessed 3 months after the procedure. Patients will be considered as having a good response if their level of pain decreases by over 30%. The number of participants having a good clinical response will be compared between the patients presenting a bursitis and those without bursitis. The comparison will be made using a Chi-2 test. Others parameters will be studied: reduction in pain 6 weeks after the injection, reduction in shoulder disability 6 weeks and 3 months after the injection. Other ultrasound lesions will be collected so as X-ray features to search other factors associated with the presence or absence of a good therapeutic response (details in secondary outcomes).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: September 1, 2021
• Est. primary completion date: March 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Major patients with manifestations of rotator cuff tendinopathy referred to our rheumatology department to receive an ultrasound-guided subacromial injection.

Exclusion Criteria:

• Patients refusing to participate
• Allergic to local anesthetics
• Shoulder involvement of an inflammatory rheumatic disease
• History of shoulder surgery
• Shoulder instability
• Glenohumeral osteoarthritis
• Frozen shoulder
• Extended rotator cuff tear
• Tendinous calcification > 0.5 cm
• Pregnant women
• Minors
• Majors under guardianship
• Patient inappropriate for entry into this study according to the judgment of the investigator

Related Conditions & MeSH terms

• Bursitis
• Rotator Cuff Tendinopathy
• Tendinopathy

Intervention

Other:
• Infiltration
The subacromial injection will be performed under ultrasound guidance to accurately inject the subacromial bursae. After skin disinfection with povidone, the injection will be performed with a 21G needle. The bursae will be injected with 2 ml of lidocaine 2% and 1 ml of betamethasone.

Locations

Country	Name	City	State
France	Chu de Nantes	Nantes

Sponsors (1)

Lead Sponsor	Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction in shoulder pain 3 months after the subacromial corticosteroid injection	The primary outcome is the presence of a therapeutic response 3 months after the intervention. The level of pain will be assessed by a visual analogic pain scale of 0 (absence of pain) to 10 centimeters (maximal pain).; Participants will be considered as good responders if their level of pain decreases more than 30 percent.; Safety issue: No	3 months
Secondary	Reduction in shoulder pain 6 weeks after the subacromial steroid injection.	Presence of a therapeutic response 6 weeks after the intervention considering the reduction in pain between day 0 and Week 6 and assessed with the same scale as the primary outcome. Participants will be considered as good responders if their level of pain decreases more than 30 percent.	6 weeks after the intervention
Secondary	Reduction in OSS score (Oxford Shoulder Score) 6 weeks and 3 months after the injection	The OSS is a 12-item shoulder-specific questionnaire that was developed, with patients, for the assessment of shoulder pain and function. Items refer to the past 4 weeks and each offers five ordinal response options. These were scored from 1 to 5 (5 = most severe) and then conbined to produce a single score with a range from 12 (least difficulties) to 60 (most difficulties).	data from Day 0, Week 6 and Month 3
Secondary	Presence of other ultrasound lesions associated with a good response to steroid injection	The ultrasound lesions collected just before the injection will be : Bursitis: the bursitis is defined by a thickening of more than 2 mm of the subacromial bursae.; Tendinous lesions (supra-spinatus, infra-spinatus or sub-scapularis): tendon thickening, hypoechoic density, presence of microcalcification, partial or complete tear; Effusion of long head of biceps tendon sheath; Acromio-clavicular joint lesions = synovitis, presence of Doppler flow, osteophytes	data from Day 0, Week 6 and Month 3
Secondary	Presence of radiographic abnormalities associated with a good response.	X-ray data = Acromion Morphology according to Park's classification, Critical Shoulder Angle, acromioclavicular osteoarthritis	data from Day 0, Week 6 and Month 3
Secondary	Steroid injection safety	Adverse events will be collected after the procedure and during follow-up.	data from Day 0, Week 6 and Month 3